CytomX Therapeutics, Inc. announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company?s board of directors. Dr. Su is an accomplished physician executive with nearly three decades of experience leading oncology research and development and commercial organizations. Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors.

During his tenure at Marengo, Dr. Su has led the teams progressing the company?s lead asset into clinical trials, grown its leading-edge pipeline, and brokered a $1.6 billion partnership with Ipsen. Prior to joining Marengo, Dr. Su was senior vice president and global head of the oncology business franchise for Merck KGaA. Before that, he was the chief medical officer at EMD Serono.

Dr. Su also held increasing leadership roles at Sanofi and GlaxoSmithKline. Before joining the industry, he served on the faculty of Duke University Medical School, where he led early oncology clinical studies focused on mRNA-based and cell-based immunotherapy, and at University of Florida, where he was the director of the cell and gene therapy program. Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).

Dr. Su received his M.D. from Technical University of Dresden in Germany and his M.B.A. from the University of Toronto, Rotman School of Management.